Interestingly, despite extensive validation of the effects of HMGCR inhibition on cardiometabolic traits by previous studies [44, 45], we observed HEIDI significance for the association of HMGCR expression in blood with CAD and LDL-C (Fig. 3), which suggested that the variant associated with HMGCR expression was distinct from those associated with CAD risk and LDL-C levels. The gene discussed is HMGCR; the disease is coronary artery disorder.